nick terrell has all the details. >> reporter: they're some of the biggest names in pharmaceuticals.fizer and merck. often rivals, coming together now to battle cancer. the companies said today they plan to collaborate to test two drugs in combination. >> it's a scientific community, they learn more about cancer, they're finding new ways to treat cancer. and a lot has to do with combination therapy. the combination therapy allows drugs to work on multiple mechanisms of action so they can have a more effective way of treating the cancer over the long-term. >> pfizer's drug is approved to treat lung cancer. a targeted therapy thought to drive the disease. merck's therapy is under review at the fda. it's in a new class, drugs that harness the immune system to fight cancer. it's also known by its target, pd-1. >> pd-1 is a molecule found relatively recently that seems to tamp down immune responses. and so if you block it, under circumstances where there's an immune response already there, directed against the tumor, if you block that, then you can now reveal that immune response, and the